Shanghai Pharmaceuticals Got ￥120.8 Billion Revenue in 2016
date：2017-12-26
browse：（960）
Keyword：
Shanghai Pharmaceuticals (601607.SH; 2607.HK) released its performance report of 2016. In 2016, Shanghai Pharmaceuticals realized an operating revenue of ￥120,765 million with a year-on-year growth of 14.45%; and its net profit saw a year-on-year growth of 11.10%, reaching ￥3,196 million. After entering the comprehensive health area through international M&A, the company has completed the privatization project of the Australian listed company, Vitaco Holdings Limited (“Vitaco”), and acquired 60% stock rights of Vitaco at the cost of ￥930 million in cash. The acquisition was a key measure for Shanghai Pharmaceuticals to enter the comprehensive health industry, which not only brought the company the future revenue from the industry development, but also promoted the international development of the company.
The latest article
- White Paper on Bone and Joint Health of Chinese Consumers 2020
- Yili Dairy launched high-protein yogurt, focusing on sport people
- Sinopharm Xingsha launched the Japan's Champion probiotics
- China has introduced its first policy to support the industrial hemp industry
- Beyond Meat became the first overseas Artificial Meat company to set up a factory in China
- Nongfu Spring's market value exceeded HK $370 billion on its first day
- German infant nutrition brand Amykon launched two probiotics in China
- The revenue of Besunyoung in the first half year is about 610 million yuan
- Jellly candy and powder included in the health food filing dosage form in China
- H&H Group net profit increased by 9% for the first half of year
